Novo Nordisk A/S Common Stock (NVO)

As of late February 2026, the financial narrative of the past two years has been dominated by a singular force in the healthcare sector: Eli Lilly & Company (NYSE: LLY). Once considered a traditional "Big Pharma" mainstay, Lilly has transcended its industry peers to become a high-octane growth engine, recently flirting

As of February 27, 2026, the narrative surrounding Novo Nordisk (NYSE: NVO) has undergone a dramatic transformation. For the better part of three years, the Danish pharmaceutical giant was the undisputed "darling" of the global equity markets, propelled by the unprecedented success of its GLP-1 (glucagon-like peptide-1) agonists, Ozempic and Wegovy. However, the early months [...]

Hims & Hers is facing some well-deserved pushback from Novo Nordisk, but the big picture is still promising.

The maker of Wegovy hasn't said its last words just yet.

The weight-loss drug innovator is falling behind in the industry and facing major pricing pressures.

As the final week of February 2026 draws to a close, the financial markets have emerged from what analysts are calling the most consequential “Heavyweight Week” of the post-pandemic era. The triple-threat earnings reports from Alphabet Inc. (NASDAQ: GOOGL), Qualcomm Inc. (NASDAQ: QCOM), and Eli Lilly and Company (NYSE: LLY)

As of February 26, 2026, Hims & Hers Health, Inc. (NYSE: HIMS) finds itself at the center of one of the most polarized debates in the modern healthcare sector. Once the "poster child" of the 2024-2025 telehealth gold rush, the company is currently navigating a period of intense volatility. After a meteoric rise fueled by [...]

How fast can Hims & Hers grow without selling GLP-1 drugs? Maybe a lot faster than you think.

Investors weigh steep GLP‑1 price cuts against a multibillion‑dollar oral obesity push, fresh analyst caution, and a new partnership, today, Feb. 25, 2026.

Eli Lilly has seen revenue and earnings soar in recent years.

Although pegged as a weight-loss stock, this drug maker's core business has long been diabetes.

Novo Nordisk will lead global development, regulatory approval, manufacturing, and commercialization of the resulting products.

Novo Nordisk (NYSE: NVO) announced plans to cut the list prices of these drugs by up to 50% in the U.S. starting in 2027, on Tuesday.

It would be a near-miracle gain.

Investors worried that the company could take quite a revenue hit due to a competitor's move.

Shares of Novo Nordisk and Eli Lilly slipped in afternoon trade after the former announced a reduction in the list prices of its weight loss drugs, Ozempic and Wegovy.

According to a report by The Wall Street Journal, Ozempic and Wegovy prices will start at a list price of $675 a month, effective Jan. 1, 2027.

Developed in partnership with United Laboratories International Holdings, Novo Nordisk said that UBT251 delivered up to 19.7% mean weight loss after 24 weeks in a phase 2 trial in China.

Is this the best way to cash in on the weight-loss gold rush?

Today, Feb. 23, 2026, a pivotal obesity‑drug trial setback forces investors to rethink Novo Nordisk’s strategy.

AI jitters, tariff shock, and looming Nvidia results have investors fleeing growth for perceived safety, today, Feb. 23, 2026.

The undisputed reign of Novo Nordisk in the weight-loss drug sector faced its most severe challenge to date on February 23, 2026, as the company’s US-traded shares (NYSE: NVO) plummeted 15.1% in a single session. The massive sell-off, which erased approximately $100 billion in market capitalization, was triggered

A potential competitive threat to Viking's phase 3 weight-loss drug VK2735 was just dealt a major blow.